SCHEMBL18558129

SCHEMBL18558129

O=C(/N=C(/Nc1cc(F)cc(Cl)c1)Nc1cc(-c2cccc(Cl)c2)[nH]n1)c1ccc(F)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 2/20 0.45
CYP2D6 P10635 1/20 0.44
RAB9A P51151 6/20 0.44
NPC1 O15118 5/20 0.44
MAPT P10636 1/20 0.44
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
FLT3 P36888 4/20 0.38
AURKA O14965 2/20 0.38
FLT1 P17948 2/20 0.38
KDR P35968 1/20 0.38
NR1I2 O75469 1/20 0.37
AHR P35869 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KCNH2 Q12809 1/20 0.36
GAK O14976 1/20 0.36
PDGFRB P09619 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19362711 0.93 RAB9A (0.53) NPY5RCYP2D6RAB9ANPC1MAPT
SCHEMBL18557848 0.91 RAB9A (0.42) NPY5RCYP2D6RAB9ANPC1MAPT
SCHEMBL17089615 0.91 CYP2D6 (0.43) NPY5RCYP2D6RAB9ANPC1MAPT
SCHEMBL19362724 0.89 CYP2D6 (0.48) NPY5RCYP2D6RAB9ANPC1MAPT
SCHEMBL9920888 0.84 NPC1 (0.43) CYP2D6RAB9ANPC1MAPTMEN1
SCHEMBL19361371 0.84 RAB9A (0.52) NPY5RCYP2D6RAB9ANPC1MAPT
SCHEMBL19041677 0.83 CYP2D6 (0.39) CYP2D6RAB9ANPC1MAPTMEN1
SCHEMBL18162905 0.83 CYP2D6 (0.52) CYP2D6RAB9ANPC1MAPTMEN1
SCHEMBL9921100 0.83 CYP2D6 (0.39) CYP2D6RAB9ANPC1MAPTMEN1
SCHEMBL19362745 0.82 CYP2D6 (0.46) NPY5RCYP2D6RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9580388-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-02-28 US disclosed